110 related articles for article (PubMed ID: 16484318)
1. Comeback for glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions for saphenous vein bypass grafts: may be for distal protection with filter-based devices?
Niemelä KO
Eur Heart J; 2006 Apr; 27(8):891-2. PubMed ID: 16484318
[No Abstract] [Full Text] [Related]
2. The evolving role of glycoprotein (GP) IIb/IIIa receptor blockade during percutaneous coronary intervention of saphenous vein bypass grafts.
D'Agate DJ; Patel S; Coppola JT; Ambrose JA
J Invasive Cardiol; 2004 Sep; 16(9):500-3. PubMed ID: 15353833
[No Abstract] [Full Text] [Related]
3. Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes.
Karha J; Gurm HS; Rajagopal V; Fathi R; Bavry AA; Brener SJ; Lincoff AM; Ellis SG; Bhatt DL
Am J Cardiol; 2006 Oct; 98(7):906-10. PubMed ID: 16996871
[TBL] [Abstract][Full Text] [Related]
4. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection.
Jonas M; Stone GW; Mehran R; Hermiller J; Feldman R; Herrmann HC; Cox DA; Kuntz RE; Popma JJ; Rogers C;
Eur Heart J; 2006 Apr; 27(8):920-8. PubMed ID: 16415300
[TBL] [Abstract][Full Text] [Related]
5. [Role of glycoprotein IIb/IIIa inhibitors in the treatment of degenerated aortocoronary saphenous vein grafts].
Brück M; Ludwig J; Flachskampf FA; Daniel WG
Z Kardiol; 2002 Jan; 91(1):16-23. PubMed ID: 11963202
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts.
Stone GW; Rogers C; Hermiller J; Feldman R; Hall P; Haber R; Masud A; Cambier P; Caputo RP; Turco M; Kovach R; Brodie B; Herrmann HC; Kuntz RE; Popma JJ; Ramee S; Cox DA;
Circulation; 2003 Aug; 108(5):548-53. PubMed ID: 12874191
[TBL] [Abstract][Full Text] [Related]
7. [Sixty-four cases of percutaneous coronary angioplasty on saphenous vein bypass grafts].
Li ZZ; Sidney L; Juergens CP; Zhu XL; Tao Y; Liu T; Wang S; Li Y
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Mar; 33(3):221-3. PubMed ID: 15929815
[TBL] [Abstract][Full Text] [Related]
8. Percutaneous intervention of a bifurcating saphenous vein graft with simultaneous dual-limb filter wire protection.
Lanzieri M
Catheter Cardiovasc Interv; 2004 Nov; 63(3):307-9. PubMed ID: 15505854
[TBL] [Abstract][Full Text] [Related]
9. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients.
Tricoci P; Peterson ED
J Interv Cardiol; 2006 Oct; 19(5):449-55. PubMed ID: 17020570
[TBL] [Abstract][Full Text] [Related]
10. [Acute coronary ischemic syndrome without ST elevation. Role of glycoprotein IIB/IIIA inhibitors and percutaneous coronary interventions].
Peña Duque MA
Arch Cardiol Mex; 2006; 76 Suppl 2():S249-51. PubMed ID: 17017111
[TBL] [Abstract][Full Text] [Related]
11. Letter regarding article by Hlatky et al, "medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease".
Osman F; Qaisar S; Pitt M
Circulation; 2005 Apr; 111(13):e176-7; author reply e176-7. PubMed ID: 15811864
[No Abstract] [Full Text] [Related]
12. Percutaneous coronary intervention of or through saphenous vein grafts or internal mammary arteries: the impact of stents, adjunctive pharmacology, and multicomponent distal protection.
Morrison DA; Thai H; Goldman S; Felix E; Hernandez J
Catheter Cardiovasc Interv; 2006 Apr; 67(4):571-9. PubMed ID: 16547927
[TBL] [Abstract][Full Text] [Related]
13. [Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions].
Fettser DV; Preobrazhenskiĭ DV; Batyraliev TA; Sidorenko BA; Aĭtach V
Ter Arkh; 2009; 81(1):84-7. PubMed ID: 19253720
[No Abstract] [Full Text] [Related]
14. Embolic protection devices in saphenous percutaneous intervention.
Morís C; Lozano I; Martín M; Rondán J; Avanzas P
EuroIntervention; 2009 May; 5 Suppl D():D45-50. PubMed ID: 19736070
[TBL] [Abstract][Full Text] [Related]
15. GP IIb/IIIa blockade during peripheral artery interventions.
Tepe G; Wiskirchen J; Pereira P; Claussen CD; Miller S; Duda SH
Cardiovasc Intervent Radiol; 2008; 31(1):8-13. PubMed ID: 17479207
[TBL] [Abstract][Full Text] [Related]
16. Distal embolic protection for SVG interventions: can we afford not to use it?
Shaia N; Heuser RR
J Interv Cardiol; 2005 Dec; 18(6):481-4. PubMed ID: 16336429
[TBL] [Abstract][Full Text] [Related]
17. Saphenous vein graft intervention: a review.
Hindnavis V; Cho SH; Goldberg S
J Invasive Cardiol; 2012 Feb; 24(2):64-71. PubMed ID: 22294536
[TBL] [Abstract][Full Text] [Related]
18. Percutaneous treatment of a single saphenous vein graft with two different protection devices.
Bedogni F; Morici N; Brambilla N
J Invasive Cardiol; 2008 Jun; 20(6):E180-2. PubMed ID: 18523332
[TBL] [Abstract][Full Text] [Related]
19. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial.
Mauri L; Cox D; Hermiller J; Massaro J; Wahr J; Tay SW; Jonas M; Popma JJ; Pavliska J; Wahr D; Rogers C
J Am Coll Cardiol; 2007 Oct; 50(15):1442-9. PubMed ID: 17919563
[TBL] [Abstract][Full Text] [Related]
20. Current status of distal embolization in percutaneous coronary intervention: mechanical and pharmacological strategies.
Haeck JD; Verouden NJ; Henriques JP; Koch KT
Future Cardiol; 2009 Jul; 5(4):385-402. PubMed ID: 19656063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
